Medical Oncology

, 31:177 | Cite as

Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma

  • Fan-Long Meng
  • Wei WangEmail author
  • Wei-Dong JiaEmail author
Original Paper


The aim of this study was to explore the diagnostic and prognostic value of serum microRNAs (miRNAs) in hepatitis B viral (HBV)-related hepatocellular carcinoma (HCC). We retrospectively analyzed clinical data of 84 consecutive patients with HBV-related HCC who underwent curative resection. Additionally, we enrolled 46 healthy controls and 31 patients with chronic liver disease (CLD). Serum levels of miR-155-5p, miR-24-3p, miR-490-3p, miR-210-3p, and miR-335-5p were measured. Associations of serum miRNAs with clinicopathological factors were evaluated. Receiver operating characteristic curves were established for discriminating HCC patients from CLD patients, and the area under the curve (AUC) was calculated. Overall survival (OS) and disease-free survival (DFS) were examined by the Kaplan–Meier method. Prognostic factors were determined by multivariate Cox analysis. Consequently, serum miR-24-3p levels were significantly greater in HCC patients than healthy controls and CLD patients. Serum miR-24-3p was significantly associated with vascular invasion in HCC patients. Serum miR-24-3p discriminated HCC patients from CLD, with an AUC of 0.636 [95 % confidence interval (CI) 0.524–0.748]. Combined serum alpha-fetoprotein (AFP) and miR-24-3p had an increased AUC of 0.834 (95 % CI 0.745–0.923; P < 0.001). Elevated serum miR-24-3p was an independent poor prognostic factor for OS and DFS of HCC patients. In conclusion, the combination of serum miR-24-3p and AFP improves the diagnostic accuracy for HCC prediction compared to each biomarker alone. High serum miR-24-3p level is an independent predictor of poor OS and DFS in patients with HBV-related HCC.


Circulating miRNAs miR-24-3p Hepatocellular carcinoma Diagnosis Prognosis 





Analysis of variance


Area under the curve


Confidence interval


Chronic liver disease


Des-γ-carboxy prothrombin


Disease-free survival


Hepatitis B viral


Hepatocellular carcinoma




Overall survival


Radiofrequency ablation


Receiver operating characteristic


Tumor node metastasis



This work was partly supported by the National Natural Science Foundation of China (Nos. 81201906 and 81172364) and Key Research Project of Anhui Provincial Health Department (No. 2010A006).

Conflict of interest

The authors declare that they have no competing financial interests.


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Suppl 4):5–13.PubMedCrossRefGoogle Scholar
  3. 3.
    Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis. 2006;26:385–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Abdalla MA, Haj-Ahmad Y. Promising candidate urinary MicroRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. J Cancer. 2012;3:19–31.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.PubMedCrossRefGoogle Scholar
  7. 7.
    Kutay H, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem. 2006;99:671–8.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 2005;15:563–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X. miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci. 2011;56:2009–16.PubMedCrossRefGoogle Scholar
  10. 10.
    Wu W, Sun M, Zou GM, Chen J. MicroRNA and cancer: current status and prospective. Int J Cancer. 2007;120:953–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Visone R, Petrocca F, Croce CM. Micro-RNAs in gastrointestinal and liver disease. Gastroenterology. 2008;135:1866–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Iorio MV, et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 2009;69:2195–200.PubMedCrossRefGoogle Scholar
  13. 13.
    Garzon R, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood. 2009;114:5331–41.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Mitchell PS, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–8.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Ying Q, et al. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology. 2011;54:2064–75.PubMedCrossRefGoogle Scholar
  16. 16.
    Dohi O, et al. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol. 2013;42:411–8.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Huang YH, et al. Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS One. 2012;7:e37188.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Zhang LY, Liu M, Li X, Tang H. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem. 2013;288:4035–47.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Huang S, et al. Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer. 2008;123:972–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50:298–301.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Lawrie CH, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Du WW, et al. MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. J Cell Sci. 2013;126:1440–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Li A, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res. 2013;19:3600–10.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Franchina T, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol. 2014;229:97–9.PubMedGoogle Scholar
  25. 25.
    Liu YX, et al. MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis. Biomed Res Int. 2014;2014:482926.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Hatziapostolou M, et al. An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011;147:1233–47.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Li X, et al. c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2. J Biol Chem. 2013;288:18121–33.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Qi J, Wang J, Katayama H, Sen S, Liu SM. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma. 2013;60:135–42.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Zhang ZQ, et al. Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol. 2014;9:135.PubMedCrossRefGoogle Scholar
  30. 30.
    Le HB, et al. Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med Oncol. 2012;29:3190–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Kurowska-Stolarska M, et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci USA. 2011;108:11193–8.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Hepatic Surgery, Anhui Provincial HospitalAnhui Medical UniversityHefeiPeople’s Republic of China
  2. 2.Department of Medical Oncology, Anhui Provincial HospitalAnhui Medical UniversityHefeiPeople’s Republic of China

Personalised recommendations